Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Founder mutations characterise the mutation panorama in 200 Swedish index cases referred for Long QT syndrome genetic testing

  • Eva-Lena Stattin1Email author,
  • Ida Maria Boström1,
  • Annika Winbo2,
  • Kristina Cederquist1,
  • Jenni Jonasson1,
  • Björn-Anders Jonsson1,
  • Ulla-Britt Diamant3,
  • Steen M Jensen3,
  • Annika Rydberg2 and
  • Anna Norberg1
BMC Cardiovascular DisordersBMC series ¿ open, inclusive and trusted201212:95

DOI: 10.1186/1471-2261-12-95

Received: 28 June 2012

Accepted: 10 October 2012

Published: 25 October 2012

Abstract

Background

Long QT syndrome (LQTS) is an inherited arrhythmic disorder characterised by prolongation of the QT interval on ECG, presence of syncope and sudden death. The symptoms in LQTS patients are highly variable, and genotype influences the clinical course. This study aims to report the spectrum of LQTS mutations in a Swedish cohort.

Methods

Between March 2006 and October 2009, two hundred, unrelated index cases were referred to the Department of Clinical Genetics, Umeå University Hospital, Sweden, for LQTS genetic testing. We scanned five of the LQTS-susceptibility genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) for mutations by DHPLC and/or sequencing. We applied MLPA to detect large deletions or duplications in the KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 genes. Furthermore, the gene RYR2 was screened in 36 selected LQTS genotype-negative patients to detect cases with the clinically overlapping disease catecholaminergic polymorphic ventricular tachycardia (CPVT).

Results

In total, a disease-causing mutation was identified in 103 of the 200 (52%) index cases. Of these, altered exon copy numbers in the KCNH2 gene accounted for 2% of the mutations, whereas a RYR2 mutation accounted for 3% of the mutations. The genotype-positive cases stemmed from 64 distinct mutations, of which 28% were novel to this cohort. The majority of the distinct mutations were found in a single case (80%), whereas 20% of the mutations were observed more than once. Two founder mutations, KCNQ1 p.Y111C and KCNQ1 p.R518*, accounted for 25% of the genotype-positive index cases. Genetic cascade screening of 481 relatives to the 103 index cases with an identified mutation revealed 41% mutation carriers who were at risk of cardiac events such as syncope or sudden unexpected death.

Conclusion

In this cohort of Swedish index cases with suspected LQTS, a disease-causing mutation was identified in 52% of the referred patients. Copy number variations explained 2% of the mutations and 3 of 36 selected cases (8%) harboured a mutation in the RYR2 gene. The mutation panorama is characterised by founder mutations (25%), even so, this cohort increases the amount of known LQTS-associated mutations, as approximately one-third (28%) of the detected mutations were unique.

Keywords

Arrhythmia Long QT syndrome Ion-channel Founder mutation Variant of unknown significance

Background

Long QT syndrome (LQTS) is an autosomal dominant inherited arrhythmogenic disease and a significant cause of sudden cardiac death (SCD), usually in young and otherwise healthy individuals. LQTS is characterised by delayed ventricular repolarisation, seen as prolongation of the QT-interval on the electrocardiogram (ECG), which predisposes to Torsade-de-Pointes (TdP) and subsequent sudden death by ventricular fibrillation [1, 2]. TdP or ventricular tachyarrhythmia is often self-terminating and presents as syncope with loss of consciousness, the most frequent symptom of LQTS. The phenotype is highly variable in expressivity and incomplete in penetrance [3]. Although the majority of LQTS patients show a diagnostic prolongation of the QT-interval on resting ECG, a normal ECG with a normal QTc is not enough to rule out LQTS, since up to approximately 40% of the patients may present with a normal QT-interval. A LQTS mutation carrier without prolonged QTc has a 10% risk of major cardiac events by the age of 40 years when left without treatment [4]. Cardiac events are often prompted by physical activity or by intense emotion or stress, but can also occur at rest or during sleep [5, 6]. Exercise-induced syncope can also be caused by another inherited ion-channel disease, named catecholaminergic polymorphic ventricular tachycardia (CPVT), which is characterised by cardiac electrical instability exacerbated by acute activation of the adrenergic nervous system [7]. Some patients suspected to have LQTS might actually have CPVT, since there is a clinical overlap between these disorders [8, 9].

The prevalence of LQTS has been estimated to 1/2,000 in the population [10]. To date, 13 different genes have been associated with LQTS, all encoding subunits of cardiac ion-channels (K+, Na+ or Ca2+) or ion-channel regulatory proteins [11]. More than 90% of the mutations are found in five of the genes (KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2), and mutation analysis of these five LQTS-causing genes reveals a mutation in about 75% of patients with a clinical diagnosis of LQTS [8, 1215]. Typically, the disease-causing mutation is a missense mutation that is unique for the family, although founder mutations have been described in different, relatively isolated populations [1618]. The occurrence of families with compound heterozygote mutations or apparent digenic inheritance, as well as rare variants of uncertain significance (VUS), further complicates the genetics of LQTS [19, 20].

First-degree relatives of a mutation carrier are at 50% risk of carrying the mutation [15], and familial cascade screening should thus be offered immediately to all families with a disease-causing mutation. Identifying additional family members at risk for the condition is of critical importance since they can get preventive treatment, thus decreasing the risk of fatal cardiac events. Here, we examine the spectrum of mutations in 200 unrelated cases referred for LQTS genetic testing in a Swedish population.

Methods

Study participants

Between March 2006 and October 2009, a total of 200 unrelated index cases (138 females; 62 males) were referred to the Department of Clinical Genetics, Umeå University Hospital, Sweden, for LQTS genetic testing as part of ordinary health care. Clinical data, including 12-lead ECG, personal history of syncope, treatment with beta-blockers, and family history, was retrospectively collected from referring physicians. The mean age of the 200 index patients at the time of ascertainment was 33 (± 20) years. Corrected QT measurements were obtained from 125 index cases by two different investigators (UBD, SJ) who were blinded to genetic status and the identity of the patient. QT interval was obtained from 12-lead ECG and corrected for heart rate using Bazett’s formula. Additionally, 12 QTc measurements of index cases were obtained from referring clinicians.

For the interpretation of novel missense variants, clinical data and blood samples from family members (both parents and siblings when available) were collected to look for co-segregation between the sequence variant and the disease in the family. Pedigrees were constructed using Cyrillic 2.1 (Cyrillic Software, Oxfordshire, United Kingdom).

The Regional Ethical Review Board of Umeå University approved this study. Data for continuous variables are presented as mean, standard deviations (SD) and/or range. The Mann–Whitney test was used for comparison of QTc, and parametric tests were used for comparison of normally distributed variables. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc. USA).

Mutation analysis

DNA was extracted from peripheral blood lymphocytes using a standard salting-out method. Genomic DNA of the 200 index cases were analysed for mutations in all protein-coding exons and their flanking splice site regions of the genes KCNQ1 (NM_000218.2 and NM_181798.1), KCNH2 (NM_000238.2 and NM_172057.1), SCN5A (NM_198056.1), KCNE1 (NM_000219.2), and KCNE2 (NM_172201.1) using PCR, denaturing high-performance liquid chromatography (DHPLC; WAVE, Transgenomic, Omaha, Neb), and/or bi-directional sequencing on the CEQ 8000 (Beckman Coulter, Fullerton, CA, USA) or the ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). All primers were checked for absence of SNPs to avoid problems with allelic dropout. All five common LQTS genes were analysed regardless of whether a mutation had been identified in one of the genes. Briefly, samples were PCR-amplified by standard methods (primer sequences available on request) and then analysed by DHPLC at one or more temperatures based on the melting profile of the fragment, as determined by Navigator Software version 2.1.0 (Transgenomic). Chromatograms were subjectively grouped, depending on the differences in the profile from normal and known polymorphic variants. Where abnormal patterns of elution were identified, the fragments were sequenced for detection of rare variants. To ensure relevance, all likely pathogenic changes were re-amplified using a different dilution of the same sample.

For cascade screening of relatives, mutation analysis was performed by sequencing as described above, or by directed mutation analysis with MGB probes using the TaqMan 7000 (Applied Biosystems, Foster City, CA, USA). In the latter case, a positive and a genotype- negative familial control was included in each analysis.

All samples were analysed for large deletions or duplications using multiplex ligation-dependent probe amplification (MLPA) with the SALSA P114-A2 kit (MRC-Holland), which covers exons 1B, 1–4, 6–13 and 15–16 for KCNQ1 (NM_000218.2 and NM_181798.1), exons 1B, 1–4, 6, 9–10 and 14 for KCNH2 (NM_000238.2 and NM_172057.1), exons 1–2 for KCNE2 (NM_172201.1), exons 2–4 for KCNE1 (NM_000219.2), and exons 2, 4, 25 and 27 for SCN5A (NM_198056.1). Thirty-six of the LQTS genotype-negative index cases were also analysed for mutations in 23 of the 105 functionally most important exons (8–15, 44–50, 83, 88–105) of the gene RYR2 (NM_001035.2). These cases were selected for RYR2 screening based on a history of sudden unexpected death (n=1), aborted cardiac arrest (n=10), ICD treatment (n=3), documented arrhythmia (n=3), and/or syncope (n=31) and/or a family history of SCD (n=11).

Defining mutation status

Sequences were evaluated using the software Sequencher™ 4.9 (Gene Codes Corporation, MI, USA). All identified LQTS-associated mutations and other variants were denoted using nomenclature recommended by Human Genome Variation Society (HGVS) [21]. To be considered as a LQTS-causing mutation, the variant must disrupt or change either the open reading frame (i.e., missense, nonsense, insertion/deletion, or frame shift mutations) or the conserved splice recognition sequences (the first two intronic nucleotides flanking the exon). Variants that did not change the open reading frame (i.e. synonymous) and intronic variants located outside of the splice recognition sequence (i.e. beyond IVS-2 or IVS+2) were not considered unless an effect on splicing could be predicted using bioinformatic tools (SpliceSiteFinder, MaxEntScan, NNSPLICE and GeneSplicer).

In addition, variants that were previously described in healthy individuals and in NCBI dbSNP as common or rare single nucleotide polymorphisms, such as KCNQ1 p.P448R, KCNE1 p.D85N, SCN5A p.H558R, or SCN5A p.A572D, were not considered to be a pathogenic mutation. In silico predictions were made for all putative mutations using the Alamut software version 1.5 (Interactive Biosoftware, Rouen, France). The Alamut software assists in evaluation of missense variants by compiling output from a number of bioinformatic prediction tools, including Polymorphism Phenotyping (PolyPhen), Sorting Intolerant From Tolerant (SIFT) and Align Grantham Variation and Grantham Deviation (Align-GVGD) [2224].

Novel missense variants were considered mutations only if an effect on the protein could be predicted using bioinformatic tools, and/or if they were absent from 100 control individuals, from the same population, and/or if they co-segregated with affected family members. For all novel missense variants, phylogenetic conservation was evaluated using the Alamut software.

Results

Subjects and clinical phenotype

DNA for mutation screening was available from 200 index patients (138 females; 62 male) referred for molecular genetic screening of long QT-syndrome to the Department of Clinical Genetics, Umeå University Hospital, Sweden. Referrals came from all six health care regions, 44 cases from the North health care region, 36 from Uppsala-Örebro, 54 from Stockholm, 43 from the West, 17 from the Southeast, and 6 cases from the South health care region. Questionnaires with clinical data were received for 125 of the index patients from referring physicians. The demographics (age, sex, QTc, symptoms, family history, and treatment with beta-blockers) of all available patients are summarised in Table 1.
Table 1

Demographics of all available, unrelated index cases referred for molecular genetic testing regarding Long QT syndrome in ordinary health care

  

Mutation positive

  
 

Total cohort

KCNQ1 positive

KCNH2 positive

SCN5A positive

KCNE1 positive

KCNE2 positive

RYR2 positive

LQTS positive

Genotype negative

Number of index cases

200

60

25

13

1

1

3

100

97

Mean age, SD range, years

33±20 0-79

36±23 0-79

29±17 3-69

24±16 0-52

49

60

20 13-32

34±21 0-79

32±20 0-76

Sex, female/male

138/62

45/15

19/6

6/7

1/0

1/0

1/2

73/27

65/32

Average QTc, SD range, ms

463±44 305-640 (136)

479±37 403-597 (41)

472±30 436-565 (20)

505±66 434-640 (10)

447-(1)

478-(1)

428 395-454 (3)

481±41 403-640 (73)

445±41 305-510 (60)

Syncope, % Yes/No

61% 72/46 (118)

53% 19/17 (36)

68% 13/6 (19)

4/4 (8)

No (1)

No (1)

1/1 (2)

55% 36/29 (65)

69% 35/16 (51)

Family history, % Yes/No

43% 49/65 (114)

76% 29/9 (38)

63% 12/7 (19)

3/3 (6)

Yes (1)

No (1)

1/1 (2)

69% 45/20 (65)

6% 3/44 (47)

Β-blockers, % Yes/No

52% 59/54 (113)

67% 22/11 (33)

68% 13/6 (19)

3/8 (8)

Yes (1)

Yes (1)

2/0 (2)

65% 40/22 (62)

35% 17/32 (49)

The numbers in parenthesis refers to the number of cases in each category. No percentages are calculated if there are less than 10 cases.

The average age at ascertainment was 33 ±20 years (range 13 days to 79 years). An ECG was available for 137 (68%) of the index cases. The average QTc among all available index patients was 463 ms (± 44). The average QTc was 479 ms (± 37) among KCNQ1 mutation carriers, 472 ms (± 30) among KCNH2 mutation carriers, and 505 ms (± 66) among SCN5A mutation carriers. The average QTc among index cases without an identified mutation was 445 ms (± 41) (Table 1). Although there was no significant difference in QTc-interval between LQT1-3 mutation carriers, there was a significant difference in QTc interval between mutation carriers and index cases without an identified mutation (Figure 1). Among the genotype-positive cases there were 33 individuals with a QTc ≥480 ms, and among the genotype-negative cases, 12 had QTc ≥480 ms. Among the patients with a prolonged QT interval, 77% carried a LQTS mutation whereas 23% had no mutation. Furthermore, 38% of the patients with a normal QT interval carried a mutation, whereas 62% had no mutation. Among subjects selected for RYR2 screening (n=36) the average QTc was 432 ms (range 347–477 ms), of which five of them had a QTc prolongation >460 ms (25 available ECG).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2261-12-95/MediaObjects/12872_2012_Article_516_Fig1_HTML.jpg
Figure 1

Graphic illustration of the difference between QTc among mutation carriers ( KCNQ1, KCNH2 and SCN5A ) compared with index cases in which no mutation was identified. The figure shows a significant QTc difference between LQTS mutation carriers and index cases without an identified mutation (KCNQ1 (n= 41) versus genotype-negative (n=61) p= 0.0001, KCNH2 (n=20) versus genotype-negative p=0.01, SCN5A (n=10) versus genotype-negative p=0.005). The scatter dot plot show QTc mean and SD.

Molecular genetic analysis

In total, a mutation was identified in 103 of the 200 (52%) index patients (Table 2).
Table 2

Pathogenic mutations in the KCNQ1, KCNE1, KCNH2, KCNE2, SCN5A and RYR2 -genes among Swedish index cases referred for genetic testing with respect to LQTS

Gene

Exon

Nucleotide change

Amino acid change

Mutation type

Region

No. of probands

Reference

KCNQ1

1

c.217C>A

p.P73T

Missense

N-term

1b

Kapplinger et al. 2009

1

c.332A>G

p.Y111C

Missense

N-term

20b

Splawski et al. 2000

 

3

c.506C>G

p.T169R

Missense

S2

1c

This studya

 

3

c.509A>G

p.E170G

Missense

S2-S3

1

This studya

 

3

c.572_576del

p.R192Cfs91*

Frame shift

S2-S3

3

Tyson et al. 1997

 

4

c.643G>A

p.V215M

Missense

S3

1

Napolitano et al. 2005

 

4

c.674C>T

p.S225L

Missense

S4

2

Priori et al 1999

 

5

c.727C>T

p.R243C

Missense

S4-S5

2

Franqueza et al.1999

 

5

c.734G>T

p.G245V

Missense

S4-S5

1

This studya

 

7

c.935C>T

p.T312I

Missense

Pore

1

Wang et al. 1996

 

7

c.944A>G

p.Y315C

Missense

Pore

1

Splawski et al. 1998

 

7

c.973G>T

p.G325W

Missense

S6

1

This studya

 

7

c.973G>A

p.G325R

Missense

S6

2

Tanaka et al. 1997

 

7

c.1023_1024delinsTT

p.L342F

Missense

S6

1

Donger et al. 1997

 

7

c.1031C>A

p.A344E

Missense

S6

1

Tester et al. 2005

 

8

c.1033-1G>C

splice

Splice site

S6

1

This studya

 

8

c.1046C>G

p.S349W

Missense

C-term

1

Splawski et al. 2000

 

8

c.1066_1071del

p.Q356_Q357del

Deletion

C-term

1

Liang et al. 2003

 

10

c.1265delA

p.K422Sfs*10

Frame shift

C-term

1

Kapplinger et al. 2009

 

12

c.1552C>T

p.R518*

Nonsense

C-term

6

Wei et al. 2000

 

12

c.1588C>T

p.Q530*

Nonsense

C-term

3

Tranebjærg et al. 1999

 

13

c.1615C>T

p.R539W

Missense

C-term

1

Chouabe et al.1997

 

13

c.1664G>A

p.R555H

Missense

C-term

1

Lupoglazoff et al. 2004

 

14

c.1697C>T

p.S566F

Missense

C-term

1

Splawski et al. 2000

 

15

c.1766G>A

p.G589D

Missense

SAR

1

Piippo et al. 2001

 

15

c.1772G>A

p.R591H

Missense

SAR

1

Neyroud et al. 1999

 

15

c.1780C>T

p.R594*

Nonsense

SAR

1

This studya

 

15

c.1781G>A

p.R594Q

Missense

SAR

1

Splawski et al. 2000

 

16

c.1801C>T

p.Q601*

Nonsense

SAR

1

This studya

 

16

c.1893dup

p.R632Qfs*20

Frame shift

C-term

1b

Neyroud et al. 1999

KCNH2

2

exon 2 duplication

 

Duplication

N-term

1

This studya

 

2

c.128A>G

p.Y43C

Missense

PAS

1

Napolitano et al. 2005

 

2

c.157G>A

p.G53S

Missense

PAS

1

Nagaoka et al. 2008

 

2

c.182A>G

p.Q61R

Missense

PAS

1c

This studya

 

2

c.235_242del

p.A79Dfs*63

Frame shift

N-term

1

This studya

 

2

c.244_252dup

p.I82_Q84dup

Insertion

PAC

1

Larsen et al. 2001

 

2

c.284A>G

p.E95G

Missense

PAC

1c

This studya

 

3

c.453delC

p.T152Pfs*14

Frame shift

N-term

2

Swan et al. 1999

 

4

c.526C>T

p.R176W

Missense

N-term

1

Swan et al. 1999

 

4

c.853_859dup

p.D287Gfs*47

Frame shift

N-term

1

This studya

 

5

c.982C>T

p.R328C

Missense

N-term

1

Tester et al. 2005

 

5

c.1094A>G

p.E365G

Missense

N-term

1

This studya

 

7

c.1655T>C

p.L552S

Missense

S5

2

Swan et al. 1999

 

7

c.1688G>A

p.W563*

Nonsense

S5

1

Berge et al. 2005

 

7

c.1706A>G

p.Y569C

Missense

S5

1

This studya

7

c. 1750G>A

p.G584S

Missense

S5

1

Swan et al. 1999

 

9

c.2254C>T

p.R752W

Missense

cNBD

1

Splawski et al. 2000

 

9

c.2312A>G

p.H771R

Missense

cNBD

1

This studya

 

10

c.2453C>T

p.S818L

Missense

cNBD

1

Berthet et al. 1999

 

9-10

exon 9-10 deletion

 

Deletion

cNBD/C-term

1

This studya

 

12

c.2959_2960del

p.L987Vfs*131

Frame shift

C-term

2

Splawski et al. 2000

 

13

c.3107dupG

p.D1037Rfs*82

Frame shift

C-term

1

Berthet et al. 1999

SCN5A

2

c.86C>T

p.A29V

Missense

N-term

1b

This studya

7

c.715A>G

p.I239V

Missense

DI-S4/S5

1

Fodstad et al. 2004

 

10

c.1231G>A

p.V411M

Missense

DI-S6

4bc

Tester et al. 2005

 

22

c.3893C>T

p.P1298L

Missense

DIII-S4

1

This studya

 

23

c.4000A>G

p.I1334V

Missense

DIII-S4/S5

1

Kapplinger et al. 2009

 

26

c.4519_4527del

p.Q1507_P1509del

Deletion

DIII-DIV

4

Keller et al. 2003

 

28

c.4877G>C

p.R1626P

Missense

DIV-S4

1

Napolitano et al. 2005

 

28

c.5350G>A

p.E1784K

Missense

C-term

1

Wei et al. 1999

KCNE1

4

c.95G>A

p.R32H

Missense

Extracellular

1b

Splawski et al. 2000

KCNE2

2

c.170T>C

p.I57T

Missense

Transmembrane

1

Abbott et al. 1999

RYR2

44

c.6737C>T

p.S2246L

Missense

Cytoplasmatic loop

2c

Priori et al. 2001

 

101

c.14553C>A

p.F4851L

Missense

TM domain

1

Hayashi et al. 2009

a Denotes a novel variant, unique to this cohort. b Compound heterozygous or homozygous mutations c de novo mutation.

Sequence analysis of the LQTS-associated genes revealed a pathogenic mutation in 98 of the 200 index patients. Furthermore, the MLPA analysis revealed 2 different CNVs in KCNH2 (exon 2 dup, and exon 9–10 del) in two patients, and the RYR2 screening revealed a pathogenic mutation in 3 of the 36 selected patients (8%). Mutations in the KCNQ1 gene were most prevalent (58%), followed by KCNH2 (24%), SCN5A (13%), RYR2 (3%), KCNE1 (1%) and KCNE2 (1%). Among the 103 mutation-positive patients, 99 had a single heterozygous mutation, whereas four female patients (4%) carried multiple mutations (KCNQ1 c.1893dup; QTc 512 ms, KCNE1 p.R32H; QTc 447 ms, KCNQ1 p.P73T, SCN5A p.V411M; QTc 464 ms and KCNQ1 p.Y111C, SCN5A p.A29V; QTc 490ms); two homozygous and two compound heterozygous mutation carriers (Table 2). None of the patients hosting double mutations displayed the phenotype of Jervell and Lange-Nielsen syndrome with clinical deafness, even though the mutations resided on different alleles.

The 103 genotype-positive patients stemmed from 64 distinct mutations, the majority of which were observed in a single case (n=51). Of the 13 mutations that were observed more than once, the six most common were KCNQ1 p.Y111C (n=20), KCNQ1 p.R518* (n=6), SCN5A p.V411M (n=4), SCN5A c.4519_4527del (n=4), KCNQ1 p.Q530* (n=3), and KCNQ1 c.572_576del (n=3).

Approximately one-third (28%) of the mutations had never previously been reported in LQTS at the time of detection, and were thus novel to this Swedish cohort. These include seven mutations in KCNQ1, nine in KCNH2 and two in SCN5A (Table 2). None of these mutations were observed in 100 analysed population-matched control individuals. Furthermore, with the exception of SCN5A p.P1298L, none were present in any of the large whole exome sequencing projects “1000 genomes project” or “NHBLI exome sequencing project (ESP)”. The putative mutation SCN5A p.P1298L was referred to as rs28937319 in dbSNP with unknown allele frequency and status probable-pathogenic. Although it has been associated with sick sinus syndrome [25], it has never been reported previously in LQTS patients, and is thus considered a novel LQTS mutation.

Evaluation of the pathogenicity in seven of the novel mutations was straightforward, including two stop mutations (KCNQ1 p.R594*, and KCNQ1 p.Q601*), two frame-shift mutations resulting in premature stops (KCNH2 p.A79Dfs*63, and KCNH2 p.D287Gfs*47), two CNVs in KCNH2 as described above, and one splice mutation in position IVS-1 (KCNQ1 c.1033-1G>C). For the eleven novel missense variants, the most important factor in determining the pathogenicity was the degree to which a missense change was conserved in orthologs and in other proteins with the same domain (Table 3). Phylogenetic alignments for the novel missense mutations are presented in Additional file 1, showing that the mutations affected highly conserved residues. In silico data and co-segregation are summarised in Table 3. In silico analysis using SIFT predicted that none of the variants seen would be tolerated, which is consistent with them being pathogenic [22]. PolyPhen conservation scores predicted seven of the variants to be probably damaging and four to be possibly damaging (Table 3) [23]. In addition, co-segregation analyses of the novel missense variants were performed in all families where samples from relatives were available. The pedigrees showed perfect co-segregation between the novel sequence variant and the disease in six families, whereas in four families no interpretation was possible due to non-penetrant or borderline QTc, and in five other families there was no samples available or missing data (data not shown). In the remaining three families, the variant had occurred de novo.
Table 3

Characteristics of the novel missense mutations unique to the Swedish cohort

Gene

Exon

Nucleotide change

Amino acid change

Region

GD

SIFT

PolyPhen

Align-GVGD

Segregation analysis

KCNQ1

3

c.506C>G

p.T169R

S2

71

not tolerated

Possibly damaging

C0

de novo

 

3

c.509A>G

p.E170G

S2-S3

98

not tolerated

Probably damaging

C0

Yes

 

5

c.734G>T

p.G245V

S4-S5

109

not tolerated

Probably damaging

C0

Borderline

 

7

c.973G>T

p.G325W

S6

184

not tolerated

Probably damaging

C65

Yes

KCNH2

2

c.182A>G

p.Q61R

PAS

43

not tolerated

Possibly damaging

C0

de novo

 

2

c.284A>G

p.E95G

PAC

98

not tolerated

Probably damaging

C0

de novo

 

5

c.1094A>G

p.E365G

N-term

98

not tolerated

Possibly damaging

C0

Yes

 

7

c.1706A>G

p.Y569C

S5

194

not tolerated

Probably damaging

C65

Borderline

 

9

c.2312A>G

p.H771R

cNBD

29

not tolerated

Probably damaging

C25

N/A

SCN5A

2

c.86C>T

p.A29V

N-term

65

not tolerated

Probably damaging

C65

Yes

 

22

c.3893C>T

p.P1298L

DIII-S4

98

not tolerated

Possibly damaging

C65

N/A

GD, Grantham distance ordered from largest difference (GD=215) between the substituted amino acids to no difference (GD=0); SIFT, sorting intolerant from tolerant; PolyPhen, Polymorphism Phenotyping predicting variants as probably damaging, possibly damaging or benign; Align-GVGD, Align Grantham variation and Grantham distance ordered from most likely (C65) to interfere with function to least likely (C0); Segregation analysis: Yes, segregation demonstrated; de novo, mutation not present in either parent; Borderline, non-penetrant or borderline QTc; N/A, samples not available or missing data.

Among the 64 distinct mutations, missense mutations were most common (70%), followed by frame-shift mutations (12.5%), nonsense mutations (8%), in-frame deletions/insertions (5%), large deletions/insertions (3%), and splice-site mutations (1.5%) (Table 4). Most of the 64 distinct mutations (47%) were localised to the transmembrane spanning and pore-forming domains, whereas 25% were localised to the N-terminus, and 28% to the C-terminus.
Table 4

Summary of population screening studies of long QT syndrome

  

Splawskiet al. 2000

Tester et al. 2005 Tester et al. 2005 a

Napolitano et al. 2005

Berge et al. 2008

Kapplinger et al. 2009

This study

Number of unrelated index cases (n)

 

262

541

430

169

2500

200

Detection rate (%) All cases/more stringent criteria (*Schwartz score ≥ 4)

 

51

50/72*

72

32/71

36

52

Novel mutations (%)

 

60

59

59

54

60

28

Multiple mutations (%)

 

-

10

5

0

9

4

Mutated gene:

KCNQ1 (%)

39

42

49

43

43

58

 

KCNH2 (%)

51

42

39

46

32

24

 

SCN5A (%)

6

15

10

9

13

13

 

KCNE1 (%)

2

0.5

2

2

3

1

 

KCNE2 (%)

2

0.5

1

-

1

1

 

RYR2 (%)

-

- 269/6a

-

- 41/17

-

3 36/8

RYR2 (n/%)

Mutation type:

Missense (%)

72

73

72

65

70

70

 

Nonsense (%)

6

6

5

14

6

8

 

In-frame ins/del (%)

5

2

14

3

3

5

 

Frame shift (%)

10

12

6

13

15

12.5

 

Splice site (%)

7

6

3

5

6

1.5

 

Large ins/del (%)

-

-

-

-

-

3

Mutation region:

N-terminal (%)

22

16

8

22

8

25

 

Transmembrane (%)

54

49

64

54

57

47

 

C-terminal (%)

24

35

28

24

35

28

In 97 of the 200 index patients, no pathogenic mutation was identified. In 19 of these patients rare missense variants were detected, that could potentially contribute to the disease phenotype, but these were not considered to be pathogenic by themselves. Additional file 2 describes all identified rare variants in the Swedish cohort with a frequency less than 5%, as well as all missense substitutions, all of which were classified as normal genetic variants.

Genetic cascade screening in family members

In the 103 unrelated families where a LQTS or CPVT disease-causing mutation was identified, a total of 481 relatives have undergone cascade genetic testing. Of these relatives, 199 (41%) were mutation carriers, while 282 (59%) did not carry a mutation. The mean number of tested individuals in each family was 5.7 (the proband included). In total, 5 of the 105 (5%) identified mutations had occurred de novo in the index patient (four LQTS mutations and one CPVT mutation, KCNQ1 p.T169R, KCNH2 p.E95G, KCNH2 p.Q61R, SCN5A p.V411M, and RYR2 p.S2246L, see Table 2). However, since both parents were not tested in all families, it is possible that this number is higher (data not shown). In one of the families with a de novo mutation (SCN5A p.V411M), two children but none of the parents were carriers, indicating possible germ-line mosaicism.

Discussion

In this study, we have determined the mutation panorama in a Swedish cohort referred for genetic LQTS testing as part of ordinary health care. Between March 2006 and October 2009, the department of Clinical Genetics in Umeå was to our knowledge the only laboratory in Sweden screening the LQTS genes. Among the 200 index patients, 64 different mutations were identified in 103 patients (52%); of which 58% occurred in KCNQ1, 24% in KCNH2, 13% in SCN5A, 3% in RYR2, 1% in KCNE1, and 1% in KCNE2. Thirteen of the mutations were found in more than one family, whereas 51 occurred only once. Among these mutations, 28% were novel at the time of detection, and had thus never been reported previously.

LQTS founder mutations

Two of the recurring mutations, KCNQ1 p.Y111C and KCNQ1 p.R518*, were identified in 26 of the 103 cases, thus accounting for approximately 25% of the mutations in the Swedish LQTS population. We have recently shown that family members carrying these mutations share a common haplotype that is specific for each mutation [26] [Abstract number 154:Winbo A. Stattin E.L. Nordin C. Persson J. Diamant U.B. Jensen S.M. Rydberg A. Origin, genotype and clinical phenotype of the Long QT Syndrome R518X/KCNQ1 mutation in Sweden. Presented at the 46th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), May 23–26 2012 in Istanbul]. The mutation KCNQ1 p.Y111C was introduced and enriched in the Ångerman River valley approximately 600 years ago [26]. Functional in-vitro studies have demonstrated that it is a “malignant” mutation with a strong dominant-negative effect, causing disturbed function of the wild-type ion channel [27, 28]. In contrast to these findings, we recently showed that the KCNQ1 p.Y111C mutation presents with a low incidence of life threatening events in a Swedish Y111C-positive LQTS population [29]. Furthermore, we showed that p.Y111C is a founder mutation in this population [26], a finding which also contrasts to in vitro-data indicating it to be a malignant mutation. One explanation for these discrepancies could be the presence of population-specific modifiers, genetic or other, such as the recently described polymorphisms in the 3’-UTR of KCNQ1, mitigating the effect of the mutated allele by reduced expression [30]. Possibly, one or several of these polymorphisms could exert its attenuating effect through the creation of a novel miRNA-binding site, a theory that has been proposed for other disorders where large differences in phenotypic expression occur [31].

The mutation KCNQ1 p.R518* has previously been reported in several populations [32, 33], as well as a founder mutation in Sweden [34] and Norway [16], although Berge et al. did not report any founder mutations in the more recent Norwegian LQTS population survey [8]. A strong founder effect has been described in the Finnish population [17]. In our study, we identified three of the Finnish founder mutations (KCNQ1 p.G589D, KCNH2 p.R176W, and KCNH2 p.L552S), as well as the two common Norwegian mutations (KCNQ1 p.R518* mentioned above, and KCNQ1 p.Q530*) in several of the patients [16, 35].

LQTS genotype-negative index cases

According to published studies, approximately 25% of index cases with the clinical phenotype of LQTS remain genotype-negative after comprehensive assessment of the three most common LQTS genes (KCNQ1, KCNH2, and SCN5A) [12, 13, 15]. In this study, 102 index patients (51%) referred for LQTS testing were negative after sequencing of the KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A genes. As in any molecular genetic study of disease, there is a possibility that these individuals have mutations missed due to technical limitations (e.g. DHPLC), or located in regions not included in the analysis; such as in the gene promotors or introns of the genes chosen for study, or in another LQTS-associated gene. However, these patients had a significantly shorter QTc, and reported family history than the mutation carriers, and some of them might therefore be suspected of not having LQTS (Figure 1, Table 1). Several publications indicate that patients suspected of having LQTS may actually have CPVT, [8, 9, 36] and that can be confirmed also in the present study. Among 36 genotype-negative index patients selected for RYR2 screening based on a history of arrhythmia, aborted cardiac arrest and/or syncope and/or a family history of SCD, we identified a disease-causing mutation in 8%. Tester et al. evaluated the prevalence of RYR2 mutations in a cohort of patients referred for screening of LQTS genes, identifying mutations in RYR2 among 6% of the 269 genotype-negative patients [9]. Berge et al. identified mutations in RYR2 in 17% of the 41 genotype-negative index patients referred for LQTS testing [8]. Thus, it is critical to recognise CPVT as an important differential diagnosis to LQTS, and to consider mutation screening of the RYR2 gene in patients who do not have a mutation in one of the LQTS-associated genes.

The presence of copy number variants (CNVs) within the LQTS disease genes have also been suggested as an explanation for the lack of identified mutations [3739]. Therefore, we performed MLPA analysis of all 200 index patients, identifying 2 CNVs in the KCNH2 gene. Thus, the yield of CNVs was 2.0% among the 100 genotype-negative index patients without an identified mutation in any of the LQTS genes or RYR2. In the study of Tester et al. CNVs were found in 4.8% of 42 patients with QTc duration ≥ 480 ms and/or a Schwartz score ≥ 4 who were negative for mutations in 12 of the LQTS-associated genes [40]. Eddy et al. identified CNVs in 11.5% of 26 patients with Schwartz score ≥ 4 who were negative for mutations in the KCNQ1, KCNH2, and SCN5A genes [38]. Barc et al. identified CNVs in 3.2% of 93 patients with Schwartz score ≥ 3 who were negative for mutations in the KCNQ1, KCNH2, and SCN5A genes [39]. These findings suggest that CNVs might be a more frequent cause of LQTS than mutations in all of the less common LQTS-associated genes (ANKB, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, and SNTA1) together [3840]. Thus, it is important to consider MLPA analysis in patients who do not possess a mutation in one of the most common LQTS-associated genes.

Genetic cascade screening in family members

A total of 481 relatives in the 103 families with an identified mutation have participated in genetic cascade screening, of which 41% were found to be mutation carriers, and 59% were not carriers. Thus, 2.9 (302/103) individuals per family carried a mutation and were thereby at risk for LQTS-associated symptoms and SCD. This finding is lower than the result in Norway, where, 4.7 (305/66) patients per family carried a heterozygote mutation [8]. In contrast to Imboden et al. [41] no female predominance among mutation carriers and no non-random inheritance, with a significant greater number of affected than expected, could be observed in this cohort.

This study compared with other population surveys

In the five largest LQTS population surveys that have been published to date, involving the five most common LQTS-causing genes (KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2), the mutation yield was 72%, 51%, 50%, 36%, and 32%, respectively (Table 4) [8, 1215]. In two of the studies, when using more stringent criteria (i.e. Schwartz score ≥ 4), the mutation detection rate was raised from 50% to 72%, and from 32% to 71%, respectively [8, 13]. In this study, we obtained a mutation detection rate of 52%, which lies in the range of the other population studies. Among individuals with a definite prolonged QTc, 77% carried a mutation, which is in line with the two studies using more stringent criteria. We were not able to categorise all the index patients, since phenotypic information was not available for all of the patients.

The largest survey, including 2,500 consecutive, unrelated LQTS patients, presented one of the lowest mutation yields of 36%. However, the degree of diagnostic relevance in the referred patients of that study could not be evaluated, also due to lack of phenotypic information.

The mutations in the KCNQ1, KCNH2 and SCN5A genes were distributed over the entire coding regions and adjacent splice sites. The vast majority were heterozygous missense mutations. The distribution of mutations between the different genes and the type of mutation concur with findings of the other population surveys. However, the rate of KCNQ1 mutations is higher in our study (58%), since both of the Swedish founder mutations p.Y111C and p.R518* are located in this gene. Most of the mutations (≈60 %) in the published surveys have not been reported previously, whereas we only identified 28% novel mutations in this study. It is possible that this lower yield is due to the more than 10 years of publications of several large LQTS studies, which suggests that the increase in new LQTS mutations is beginning to be saturated.

Probands carrying multiple mutations

Patients carrying multiple mutations have been shown to present with a more severe phenotype compared to patients carrying only one mutation [19]. In one study, the compound mutation carriers had longer QTc intervals and a younger age-at-onset compared to patients with only one mutation [19]. In this study, four of the 103 (4%) genotype-positive patients carried more than one definitely pathogenic mutation. Two of them were homozygous for the mutation and two compound heterozygote. All of them are female and have a family history of LQTS. The (homozygous) carrier of the KCNQ1 c.1893dup mutation, had a QTc prolongation of 512 ms; however, there is no information about any history of syncope or current treatment with beta-blockers. The parents of the c.1893dup mutation carrier both carried the mutation in heterozygous form; the mother had a QTc of 435 ms while the father has a QTc denoted as normal (data not shown). The KCNE1 p.R32H (homozygous) mutation carrier, had a QTc of 447 ms, is being treated with beta-blockers and has not experienced syncope. The parents of the p.R32H mutation carrier were not available for testing, but hemizygosity of the mutation in the proband was excluded by MLPA (data not shown). The carrier of the (compound heterozygote) mutations KCNQ1 p.P73T and SCN5A p.V411M, had a history of suspected seizures and syncope, and she was not treated with beta-blockers but with Phenytoin. The carrier of the (compound heterozygote) mutations KCNQ1 p.Y111C and SCN5A p.A29V, had a history of presyncope and a QTc of 490 ms.

In the Norwegian survey, no patients had more than one definitely pathogenic mutation, whereas Kapplinger et al. reported 9%, and Tester et al. reported 11% patients with multiple mutations among the genotype-positive patients [8, 13, 14]. In the study of Westenskow et al. compound mutations were reported in 12% of the genotype-positive LQTS probands. However, of the 20 probands in their study assigned as having multiple mutations, over half possessed either the KCNE1 p.D85N or KCNQ1 p.P448R common polymorphism as the “second hit” [42]. Similarly, Tester et al. reported SCN5A p.A572D as a mutation in 3 of their patients [13]. In our study, SCN5A p.A572D was identified in 3 patients, KCNQ1 p.P448R in 3 patients, and KCNE1 p.D85N in 12 patients, all of which were determined to be non-pathogenic ( Additional file 2). In four of the patients, these variants occurred together with a definitely pathogenic mutation. If we had regarded these as pathogenic mutations, our yield of multiple mutations among the genotype-positive patients would have been 8% (8/103) instead of 4%.

Sequence variants of unknown significance - polymorphisms

Missense mutations are the most frequent form of mutation in the LQTS genes, accounting for about 65-73% of the mutations in the large LQTS population surveys. Careful interpretation of identified genetic variants is important, because a missense variant may or may not cause an altered/distorted protein and a disease phenotype [43]. In this study, several of the index patients carried rare variants, such as KCNE1 p.D85N, KCNQ1 p.P448R, SCN5A p.A572D, SCN5A p.S1103Y, and SCN5A p.R1193Q. The possible effect of these missense variants is difficult to interpret and they are referred to in the literature as both mutations and functional polymorphisms [44, 45]. Although these variants might contribute to the phenotype, we did not consider these as disease-causing mutations by themselves, since careful interpretation of genetic test results is critical in clinical practice [43].

Limitations of the study

The 200 index cases were almost consecutively included; we have excluded 27 index cases with other diagnoses such as Jervell and Lange-Nielsen syndrome, Brugada Syndrome, short QT syndrome, and healthy individuals sent for LQTS-screening due to a history of first-degree relative with SUD. No selection of the patients was performed, resulting in a cohort that ranges from low suspicion of LQTS to high. Since the patients were referred for LQTS screening in ordinary health care, the clinical data were collected retrospectively and is thus not complete for all families. Only 23 of 105 exons (8–15, 44–50, 83, 88–105) of the gene RYR2 were analysed. DNA was not available for screening of all five genes in some of the individuals, and therefore it is possible that some double mutations might have been missed. Due to the lack of DNA, there were incomplete analyses of the KCNQ1 gene in three individuals, in the KCNH2 gene in two, KCNE1 in five, KCNE2 gene in four, and in the SCN5A gene in nine individuals. For the same reason MLPA was not performed in two cases.

Conclusions

The distribution of mutations between the different genes, as well as the type of mutation, concur with findings of other LQTS population surveys. In contrast, the mutation panorama in this Swedish cohort is characterised by two founder mutations in the KCNQ1 gene that accounts for one-fourth of the identified mutations. The findings of a mutation in RYR2 among 8% of the selected cases, as well as CNVs among 2% of all genotype-negative cases suggest that mutation analysis of RYR2 and MLPA analysis in a genotype-negative LQTS population is of importance and might give a higher yield than screening of the less common LQTS-associated genes.

Abbreviations

CNV: 

Copy Number Variations

CPVT: 

Catecholaminergic Polymorphic Ventricular Tachycardia

DHPLC: 

Denaturing High-Performance Liquid Chromatography

DNA: 

Deoxyribonucleic Acid, ECG, Electrocardiogram

HGVS: 

Human Genome Variation Society

LQTS: 

Long QT syndrome

MLPA: 

Multiplex Ligation-dependent Probe Amplification

PCR: 

Polymerase Chain Reaction

SCD: 

Sudden Cardiac Death

TdP: 

Torsade-de-Pointes

VUS: 

Variants of Uncertain Significance.

Declarations

Acknowledgements

This research was supported by grants from the medical faculty at Umeå University and the Swedish heart-lung foundation. We thank all the referring physicians for contribution of phenotypic data and samples. We also thank all patients and family members who have donated the samples that made this study possible. All mutational analyses performed in this study were conducted as part of ordinary health care.

Authors’ Affiliations

(1)
Department of Medical Biosciences, Medical and Clinical Genetics, Umeå University
(2)
Department of Clinical Sciences, Paediatrics, Umeå University
(3)
Heart Centre and Department of Public Health and Clinical Medicine, Umeå University

References

  1. Goldenberg I, Zareba W, Moss AJ: Long QT Syndrome. Curr Probl Cardiol. 2008, 33 (11): 629-694. 10.1016/j.cpcardiol.2008.07.002.View ArticlePubMed
  2. Kramer DB, Zimetbaum PJ: Long-QT syndrome. Cardiol Rev. 2011, 19 (5): 217-225. 10.1097/CRD.0b013e3182203504.View ArticlePubMed
  3. Ackerman MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998, 73 (3): 250-269. 10.4065/73.3.250.View ArticlePubMed
  4. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, et al: Risk stratification in the long-QT syndrome. N Engl J Med. 2003, 348 (19): 1866-1874. 10.1056/NEJMoa022147.View ArticlePubMed
  5. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, et al: Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001, 103 (1): 89-95. 10.1161/01.CIR.103.1.89.View ArticlePubMed
  6. Wilde AA, Jongbloed RJ, Doevendans PA, Duren DR, Hauer RN, van Langen IM, van Tintelen JP, Smeets HJ, Meyer H, Geelen JL: Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol. 1999, 33 (2): 327-332. 10.1016/S0735-1097(98)00578-6.View ArticlePubMed
  7. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, et al: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002, 106 (1): 69-74. 10.1161/01.CIR.0000020013.73106.D8.View ArticlePubMed
  8. Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, Rognum TO, et al: Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest. 2008, 68 (5): 362-368. 10.1080/00365510701765643.View ArticlePubMed
  9. Tester DJ, Kopplin LJ, Will ML, Ackerman MJ: Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Hear Rhythm. 2005, 2 (10): 1099-1105. 10.1016/j.hrthm.2005.07.012.View Article
  10. Roden DM: Clinical practice. Long-QT syndrome. N Engl J Med. 2008, 358 (2): 169-176. 10.1056/NEJMcp0706513.View ArticlePubMed
  11. Bokil NJ, Baisden JM, Radford DJ, Summers KM: Molecular genetics of long QT syndrome. Mol Genet Metab. 2010, 101 (1): 1-8. 10.1016/j.ymgme.2010.05.011.View ArticlePubMed
  12. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, et al: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000, 102 (10): 1178-1185. 10.1161/01.CIR.102.10.1178.View ArticlePubMed
  13. Tester DJ, Will ML, Haglund CM, Ackerman MJ: Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Hear Rhythm. 2005, 2 (5): 507-517. 10.1016/j.hrthm.2005.01.020.View Article
  14. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicoff A, Harris-Kerr C, et al: An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Hear Rhythm. 2010, 7 (1): 33-46. 10.1016/j.hrthm.2009.09.069.View Article
  15. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S: Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005, 294 (23): 2975-2980. 10.1001/jama.294.23.2975.View ArticlePubMed
  16. Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M: Jervell and Lange-Nielsen syndrome: a Norwegian perspective. Am J Med Genet. 1999, 89 (3): 137-146. 10.1002/(SICI)1096-8628(19990924)89:3<137::AID-AJMG4>3.0.CO;2-C.View ArticlePubMed
  17. Fodstad H, Swan H, Laitinen P, Piippo K, Paavonen K, Viitasalo M, Toivonen L, Kontula K: Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med. 2004, 36 (Suppl 1): 53-63.View ArticlePubMed
  18. Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazminskaya EV, Swan H, Ackerman MJ, Moss AJ, et al: The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007, 116 (21): 2366-2375. 10.1161/CIRCULATIONAHA.107.726950.View ArticlePubMed
  19. Itoh H, Shimizu W, Hayashi K, Yamagata K, Sakaguchi T, Ohno S, Makiyama T, Akao M, Ai T, Noda T, et al: Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Hear Rhythm. 2010, 7 (10): 1411-1418. 10.1016/j.hrthm.2010.06.013.View Article
  20. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AA, Ackerman MJ: Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation. 2009, 120 (18): 1752-1760. 10.1161/CIRCULATIONAHA.109.863076.PubMed CentralView ArticlePubMed
  21. Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998, 11 (1): 1-3.View ArticlePubMed
  22. Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009, 4 (7): 1073-1081.View ArticlePubMed
  23. Sunyaev S, Ramensky V, Koch I, Lathe W, Kondrashov AS, Bork P: Prediction of deleterious human alleles. Hum Mol Genet. 2001, 10 (6): 591-597. 10.1093/hmg/10.6.591.View ArticlePubMed
  24. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007, 28 (6): 622-629. 10.1002/humu.20495.View ArticlePubMed
  25. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George AL: Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest. 2003, 112 (7): 1019-1028.PubMed CentralView ArticlePubMed
  26. Winbo A, Diamant UB, Rydberg A, Persson J, Jensen SM, Stattin EL: Origin of the Swedish long QT syndrome Y111C/KCNQ1 founder mutation. Hear Rhythm. 2011, 8 (4): 541-547. 10.1016/j.hrthm.2010.11.043.View Article
  27. Jespersen T, Rasmussen HB, Grunnet M, Jensen HS, Angelo K, Dupuis DS, Vogel LK, Jorgensen NK, Klaerke DA, Olesen SP: Basolateral localisation of KCNQ1 potassium channels in MDCK cells: molecular identification of an N-terminal targeting motif. J Cell Sci. 2004, 117 (Pt 19): 4517-4526.View ArticlePubMed
  28. Dahimene S, Alcolea S, Naud P, Jourdon P, Escande D, Brasseur R, Thomas A, Baro I, Merot J: The N-terminal juxtamembranous domain of KCNQ1 is critical for channel surface expression: implications in the Romano-Ward LQT1 syndrome. Circ Res. 2006, 99 (10): 1076-1083. 10.1161/01.RES.0000250262.12219.95.View ArticlePubMed
  29. Winbo A, Diamant UB, Stattin EL, Jensen SM, Rydberg A: Low incidence of sudden cardiac death in a Swedish Y111C type 1 long-QT syndrome population. Circ Cardiovasc Genet. 2009, 2 (6): 558-564. 10.1161/CIRCGENETICS.108.825547.View ArticlePubMed
  30. Amin AS, Giudicessi JR, Tijsen AJ, Spanjaart AM, Reckman YJ, Klemens CA, Tanck MW, Kapplinger JD, Hofman N, Sinner MF, et al: Variants in the 3’ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J. 2012, 33 (6): 714-723. 10.1093/eurheartj/ehr473.PubMed CentralView ArticlePubMed
  31. Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, Cederquist K, Jonasson J: A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet. 2010, 11: 130-10.1186/1471-2350-11-130.PubMed CentralView ArticlePubMed
  32. Wei J, Fish FA, Myerburg RJ, Roden DM, George AL: Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat. 2000, 15 (4): 387-388.View ArticlePubMed
  33. Larsen LA, Fosdal I, Andersen PS, Kanters JK, Vuust J, Wettrell G, Christiansen M: Recessive Romano-Ward syndrome associated with compound heterozygosity for two mutations in the KVLQT1 gene. Eur J Hum Genet. 1999, 7 (6): 724-728. 10.1038/sj.ejhg.5200323.View ArticlePubMed
  34. Winbo A, Stattin EL, Diamant UB, Persson J, Jensen SM, Rydberg A: Prevalence, mutation spectrum, and cardiac phenotype of the Jervell and Lange-Nielsen syndrome in Sweden. Europace. 2012, [Epub ahed of print]
  35. Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, Jula A, Lahermo P, Vaananen H, Toivonen L, et al: High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med. 2009, 41 (3): 234-240. 10.1080/07853890802668530.PubMed CentralView ArticlePubMed
  36. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, Mannens MM, Wilde AA, Ackerman MJ: The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol. 2009, 54 (22): 2065-2074. 10.1016/j.jacc.2009.08.022.PubMed CentralView ArticlePubMed
  37. Koopmann TT, Alders M, Jongbloed RJ, Guerrero S, Mannens MM, Wilde AA, Bezzina CR: Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies. Hear Rhythm. 2006, 3 (1): 52-55. 10.1016/j.hrthm.2005.10.014.View Article
  38. Eddy CA, MacCormick JM, Chung SK, Crawford JR, Love DR, Rees MI, Skinner JR, Shelling AN: Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Hear Rhythm. 2008, 5 (9): 1275-1281. 10.1016/j.hrthm.2008.05.033.View Article
  39. Barc J, Briec F, Schmitt S, Kyndt F, Le Cunff M, Baron E, Vieyres C, Sacher F, Redon R, Le Caignec C, et al: Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance. J Am Coll Cardiol. 2011, 57 (1): 40-47. 10.1016/j.jacc.2010.08.621.View ArticlePubMed
  40. Tester DJ, Benton AJ, Train L, Deal B, Baudhuin LM, Ackerman MJ: Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol. 2010, 106 (8): 1124-1128. 10.1016/j.amjcard.2010.06.022.PubMed CentralView ArticlePubMed
  41. Imboden M, Swan H, Denjoy I, Van Langen IM, Latinen-Forsblom PJ, Napolitano C, Fressart V, Breithardt G, Berthet M, Priori S, et al: Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med. 2006, 355 (26): 2744-2751. 10.1056/NEJMoa042786.View ArticlePubMed
  42. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC: Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004, 109 (15): 1834-1841. 10.1161/01.CIR.0000125524.34234.13.View ArticlePubMed
  43. Refsgaard L, Holst AG, Sadjadieh G, Haunso S, Nielsen JB, Olesen MS: High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet. 2012, 20: 905-908. 10.1038/ejhg.2012.23.PubMed CentralView ArticlePubMed
  44. Tester DJ, Valdivia C, Harris-Kerr C, Alders M, Salisbury BA, Wilde AA, Makielski JC, Ackerman MJ: Epidemiologic, molecular, and functional evidence suggest A572D-SCN5A should not be considered an independent LQT3-susceptibility mutation. Hear Rhythm. 2010, 7 (7): 912-919. 10.1016/j.hrthm.2010.04.014.View Article
  45. Van Norstrand DW, Tester DJ, Ackerman MJ: Overrepresentation of the proarrhythmic, sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. Hear Rhythm. 2008, 5 (5): 712-715. 10.1016/j.hrthm.2008.02.012.View Article
  46. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2261/​12/​95/​prepub

Copyright

© Stattin et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement